mRNA therapeutics to extend healthspan entering clinical trials
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Reverses 10 years of telomere shortening with a single dose. Preclinical efficacy in fibrotic liver and lung disease. Entering IND-enabling. 50+ granted patents, 7 patent families. FDA INTERACT cleared.